clinical trial

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

Law firm Bernstein Liebhard files securities fraud class action against $SLNO, citing alleged misrepresentations regarding Phase 3 DCCR clinical trial program.

Aethlon Medical's Hemopurifier device advances to final clinical trial phase following positive safety review with no adverse events reported.

Sanofi and Regeneron's Dupixent secured Japanese regulatory approval for bullous pemphigoid, marking the drug's seventh indication in Japan with superior remission rates versus placebo.

Dupixent receives Japanese marketing authorization for bullous pemphigoid, becoming the first targeted treatment. Study showed 18% remission rate versus 4% for placebo.

Class action lawsuit filed against $SLNO alleging failure to disclose safety concerns about DCCR drug candidate, including fluid retention issues in clinical trials.

$SLNO investors urged to join class action over undisclosed DCCR safety concerns; May 5, 2026 deadline.

RTW Investments purchases $116M stake in Cogent Biosciences, raising position to 2.7% of AUM amid 360% stock surge and anticipated 2026 FDA decision on lead drug.

Bristol Myers wins FDA approval for Opdivo plus chemotherapy in untreated Hodgkin lymphoma. Stock declined 1.33% despite clinical success in Study CA209-8UT.

Novo Nordisk wins FDA approval for Wegovy HD, a higher-dose version launching in April across 70,000+ U.S. pharmacies, despite modest stock decline.

Class action lawsuit filed against REGENXBIO alleging false statements about RGX-111 gene therapy development and clinical trials, covering investors from February 2022 through January 2026.

Eli Lilly's retatrutide shows strong weight loss results in trials, but HSBC downgrades stock citing overvaluation concerns.

INmune Bio's XPro trial gains recognition at AD/PD 2026 for innovative biomarker-enriched Alzheimer's approach, securing FDA approval to advance to Phase 2b/3 registrational studies.

Taysha Gene Therapies reported $109M 2025 loss while advancing TSHA-102 gene therapy for Rett syndrome with positive safety data and FDA regulatory alignment through 2028.

Soleno Therapeutics ($SLNO) faces class action lawsuit alleging executives failed to disclose material safety concerns with its lead drug DCCR, with lead plaintiff deadline set for May 5, 2026.

Soleno Therapeutics faces securities fraud lawsuit over alleged safety misstatements in DCCR clinical trial. Stock fell 26% following August short-seller report.

Securities class action filed against RARE over alleged false statements regarding Phase III clinical trials for setrusumab. Claim deadline April 6, 2026.

ProKidney reports $270M cash reserves extending operations to mid-2027, achieves FDA alignment on accelerated approval pathway for rilparencel with Phase 3 enrollment progressing ahead of schedule.

Law firm Kahn Swick & Foti alleges Soleno Therapeutics failed to disclose material safety concerns with its flagship DCCR product, with lead plaintiff applications due May 5, 2026.

SAB Biotherapeutics prices $85M offering at $3.85/share to fund Phase 2b trials of type 1 diabetes candidate SAB-142, with closing expected March 2026.